vs
Amphastar Pharmaceuticals, Inc.（AMPH）とフォレスターリサーチ（FORR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $101.1M、フォレスターリサーチの約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -33.5%、差は46.9%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -6.5%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-4.3M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 0.5%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
フォレスターリサーチは世界的な調査・アドバイザリー企業で、業界調査、経営コンサルティング、業界イベントの開催を主な事業としています。顧客にはグローバル大手企業、テクノロジー企業、消費財分野の代表的企業が含まれ、本社は米国マサチューセッツ州ケンブリッジに置かれています。
AMPH vs FORR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $101.1M |
| 純利益 | $24.4M | $-33.9M |
| 粗利率 | 46.8% | 56.7% |
| 営業利益率 | 19.4% | -36.6% |
| 純利益率 | 13.3% | -33.5% |
| 売上前年比 | -1.8% | -6.5% |
| 純利益前年比 | -35.7% | -7941.4% |
| EPS（希薄化後） | $0.51 | $-1.75 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $101.1M | ||
| Q3 25 | $191.8M | $94.3M | ||
| Q2 25 | $174.4M | $111.7M | ||
| Q1 25 | $170.5M | $89.9M | ||
| Q4 24 | $186.5M | $108.0M | ||
| Q3 24 | $191.2M | $102.5M | ||
| Q2 24 | $182.4M | $121.8M | ||
| Q1 24 | $171.8M | $100.1M |
| Q4 25 | $24.4M | $-33.9M | ||
| Q3 25 | $17.4M | $-2.1M | ||
| Q2 25 | $31.0M | $3.9M | ||
| Q1 25 | $25.3M | $-87.3M | ||
| Q4 24 | $38.0M | $432.0K | ||
| Q3 24 | $40.4M | $-5.8M | ||
| Q2 24 | $37.9M | $6.3M | ||
| Q1 24 | $43.2M | $-6.7M |
| Q4 25 | 46.8% | 56.7% | ||
| Q3 25 | 51.4% | 60.0% | ||
| Q2 25 | 49.6% | 55.5% | ||
| Q1 25 | 50.0% | 55.9% | ||
| Q4 24 | 46.5% | 58.8% | ||
| Q3 24 | 53.3% | 60.5% | ||
| Q2 24 | 52.2% | 57.3% | ||
| Q1 24 | 52.4% | 54.9% |
| Q4 25 | 19.4% | -36.6% | ||
| Q3 25 | 13.2% | 4.7% | ||
| Q2 25 | 24.2% | 6.2% | ||
| Q1 25 | 21.9% | -97.5% | ||
| Q4 24 | 24.2% | -0.5% | ||
| Q3 24 | 29.8% | -0.7% | ||
| Q2 24 | 30.3% | 9.3% | ||
| Q1 24 | 27.9% | -9.3% |
| Q4 25 | 13.3% | -33.5% | ||
| Q3 25 | 9.0% | -2.3% | ||
| Q2 25 | 17.8% | 3.5% | ||
| Q1 25 | 14.8% | -97.1% | ||
| Q4 24 | 20.4% | 0.4% | ||
| Q3 24 | 21.1% | -5.7% | ||
| Q2 24 | 20.8% | 5.2% | ||
| Q1 24 | 25.1% | -6.7% |
| Q4 25 | $0.51 | $-1.75 | ||
| Q3 25 | $0.37 | $-0.11 | ||
| Q2 25 | $0.64 | $0.20 | ||
| Q1 25 | $0.51 | $-4.62 | ||
| Q4 24 | $0.74 | $0.02 | ||
| Q3 24 | $0.78 | $-0.30 | ||
| Q2 24 | $0.73 | $0.33 | ||
| Q1 24 | $0.81 | $-0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $63.3M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $126.5M |
| 総資産 | $1.6B | $404.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $63.3M | ||
| Q3 25 | $276.2M | $65.1M | ||
| Q2 25 | $231.8M | $67.8M | ||
| Q1 25 | $236.9M | $75.6M | ||
| Q4 24 | $221.6M | $56.1M | ||
| Q3 24 | $250.5M | $62.8M | ||
| Q2 24 | $217.8M | $58.9M | ||
| Q1 24 | $289.6M | $61.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $126.5M | ||
| Q3 25 | $776.7M | $157.7M | ||
| Q2 25 | $757.5M | $159.5M | ||
| Q1 25 | $751.3M | $147.4M | ||
| Q4 24 | $732.3M | $229.5M | ||
| Q3 24 | $727.7M | $234.3M | ||
| Q2 24 | $713.3M | $237.1M | ||
| Q1 24 | $672.4M | $230.9M |
| Q4 25 | $1.6B | $404.0M | ||
| Q3 25 | $1.7B | $414.2M | ||
| Q2 25 | $1.6B | $436.0M | ||
| Q1 25 | $1.6B | $439.8M | ||
| Q4 24 | $1.6B | $503.9M | ||
| Q3 24 | $1.5B | $505.3M | ||
| Q2 24 | $1.5B | $524.2M | ||
| Q1 24 | $1.6B | $555.7M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-3.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-4.3M |
| FCFマージンFCF / 売上 | 13.4% | -4.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $18.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-3.2M | ||
| Q3 25 | $52.6M | $1.2M | ||
| Q2 25 | $35.6M | $-3.6M | ||
| Q1 25 | $35.1M | $26.7M | ||
| Q4 24 | $29.0M | $-1.8M | ||
| Q3 24 | $60.0M | $264.0K | ||
| Q2 24 | $69.1M | $-2.9M | ||
| Q1 24 | $55.3M | $611.0K |
| Q4 25 | $24.6M | $-4.3M | ||
| Q3 25 | $47.2M | $524.0K | ||
| Q2 25 | $25.0M | $-4.2M | ||
| Q1 25 | $24.4M | $26.1M | ||
| Q4 24 | $16.6M | $-2.5M | ||
| Q3 24 | $46.2M | $-223.0K | ||
| Q2 24 | $63.1M | $-3.7M | ||
| Q1 24 | $46.5M | $-815.0K |
| Q4 25 | 13.4% | -4.2% | ||
| Q3 25 | 24.6% | 0.6% | ||
| Q2 25 | 14.3% | -3.8% | ||
| Q1 25 | 14.3% | 29.0% | ||
| Q4 24 | 8.9% | -2.3% | ||
| Q3 24 | 24.1% | -0.2% | ||
| Q2 24 | 34.6% | -3.1% | ||
| Q1 24 | 27.1% | -0.8% |
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.5% | ||
| Q1 25 | 6.3% | 0.7% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 5.1% | 1.4% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | -0.93× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | -4.24× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -0.46× | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
